Immunogenicity of Milk Protein-Containing Hydrophilic Gel Patch for Epicutaneous Immunotherapy for Milk Allergy.


Journal

Pharmaceutical research
ISSN: 1573-904X
Titre abrégé: Pharm Res
Pays: United States
ID NLM: 8406521

Informations de publication

Date de publication:
16 Jan 2020
Historique:
received: 03 06 2019
accepted: 21 10 2019
entrez: 18 1 2020
pubmed: 18 1 2020
medline: 28 2 2020
Statut: epublish

Résumé

Epicutaneous immunotherapy (EPIT) involving the skin's immune system is easy to use, painless and has a low risk of systemic side effects; it can be applied to food allergies that have a high morbidity rate in children. In this study, we evaluated the safety and efficacy of hydrophilic gel patch (HG) for EPIT. Milk protein concentrate (MPC)-containing HG was applied to the skin that maintained a barrier function or formed puncture holes with microneedle, and MPC-specific antibodies were measured. The clinical study was conducted involving patients with severe milk allergy. No specific immune response was induced when immunizing to intact skin, and antibody production was observed by forming puncture holes. It was suggested that MPC contained in HG has immunogenicity and a very small amount of MPC was delivered to intact skin. In the clinical study, the symptom induction threshold increased in four of eight subjects, allowing them to consume milk and switch to oral immunotherapy. Although local skin reactions and temporary elevation of specific IgE antibodies were observed, no systemic side effects appeared throughout the study. EPIT using HG is a safe method to enable oral administration even in patients with severe milk allergies.

Identifiants

pubmed: 31950282
doi: 10.1007/s11095-019-2728-y
pii: 10.1007/s11095-019-2728-y
doi:

Substances chimiques

Acrylic Resins 0
Milk Proteins 0
Immunoglobulin E 37341-29-0
carbopol 940 4Q93RCW27E

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

35

Références

J Allergy Clin Immunol. 2016 Apr;137(4):1258-1261.e10
pubmed: 26920463
Nat Med. 2012 May 04;18(5):736-49
pubmed: 22561837
J Allergy Clin Immunol. 2008 Jun;121(6):1331-6
pubmed: 18539191
Proc Natl Acad Sci U S A. 2013 Aug 20;110(34):13921-6
pubmed: 23918359
Clin Exp Allergy. 2011 Sep;41(9):1177-200
pubmed: 21848757
Vaccine. 2012 Feb 27;30(10):1847-54
pubmed: 22230592
J Allergy Clin Immunol. 1997 Jun;99(6 Pt 1):744-51
pubmed: 9215240
J Allergy Clin Immunol. 2014 Feb;133(2):291-307; quiz 308
pubmed: 24388012
Annu Rev Immunol. 1999;17:931-72
pubmed: 10358778
J Control Release. 2011 Jan 5;149(1):15-20
pubmed: 20493218
J Allergy Clin Immunol. 2014 Jul;134(1):75-81
pubmed: 24794684
Nat Biotechnol. 2004 Feb;22(2):165-7
pubmed: 14755286
Sci Transl Med. 2013 Jan 30;5(170):170ra16
pubmed: 23363980
Clin Exp Allergy. 2012 Mar;42(3):363-74
pubmed: 22356141
Nat Immunol. 2013 Jun;14(6):536-42
pubmed: 23685824
World Allergy Organ J. 2013 Dec 04;6(1):21
pubmed: 24304599
Curr Opin Allergy Clin Immunol. 2013 Jun;13(3):275-9
pubmed: 23510952
J Allergy Clin Immunol. 1997 Dec;100(6 Pt 1):760-6
pubmed: 9438483
J Allergy Clin Immunol. 1992 Aug;90(2):256-62
pubmed: 1500630
Clin Ther. 2000 Mar;22(3):329-41
pubmed: 10963287
J Allergy Clin Immunol. 2017 Apr;139(4):1242-1252.e9
pubmed: 28091362
Biol Pharm Bull. 2011;34(4):586-9
pubmed: 21467651
J Control Release. 2008 Oct 21;131(2):113-20
pubmed: 18700159
Trends Pharmacol Sci. 2009 Jun;30(6):287-95
pubmed: 19439372
J Allergy Clin Immunol. 2009 Nov;124(5):997-1002
pubmed: 19733905
J Allergy Clin Immunol. 2008 Dec;122(6):1154-60
pubmed: 18951617
World Allergy Organ J. 2015 May 14;8(1):17
pubmed: 26023323
Int J Pharm. 2017 Oct 30;532(1):374-383
pubmed: 28855138
Int Arch Allergy Immunol. 2011;154(4):299-309
pubmed: 20962535
Biol Pharm Bull. 2011;34(12):1835-40
pubmed: 22130239
J Allergy Clin Immunol. 2017 Apr;139(4):1135-1136
pubmed: 27964851
J Pharm Sci. 2013 Jun;102(6):1936-1947
pubmed: 23585300

Auteurs

Sayami Ito (S)

Project for Vaccine and Immune Regulation, Laboratory of Vaccine and Immune Regulation (BIKEN), Graduate School of Pharmaceutical Sciences, Osaka University, 1-6 Yamadaoka, Suita, Osaka, 565-0871, Japan.

Sachiko Hirobe (S)

Advanced Research of Medical and Pharmaceutical Sciences, Graduate School of Pharmaceutical Sciences, Osaka University, 1-6 Yamadaoka Suita, Osaka, 565-0871, Japan.
Project of Clinical Pharmacology and Therapeutics, Center for Advanced Education and Research in Pharmaceutical Sciences, Graduate School of Pharmaceutical Sciences, Osaka University, 1-6 Yamadaoka, Suita, Osaka, 565-0871, Japan.

Yu Kuwabara (Y)

Allergy Center and Department of Clinical Research, Mie National Hospital, 357 Osato-kubota, Tsu, Mie, 514-0125, Japan.

Mizuho Nagao (M)

Allergy Center and Department of Clinical Research, Mie National Hospital, 357 Osato-kubota, Tsu, Mie, 514-0125, Japan.

Mio Saito (M)

CosMED Pharmaceutical Co. Ltd, 32 Higashikujokawanishi-cho Minami-ku, Kyoto, 601-8014, Japan.

Ying-Shu Quan (YS)

CosMED Pharmaceutical Co. Ltd, 32 Higashikujokawanishi-cho Minami-ku, Kyoto, 601-8014, Japan.

Fumio Kamiyama (F)

CosMED Pharmaceutical Co. Ltd, 32 Higashikujokawanishi-cho Minami-ku, Kyoto, 601-8014, Japan.

Takao Fujisawa (T)

Allergy Center and Department of Clinical Research, Mie National Hospital, 357 Osato-kubota, Tsu, Mie, 514-0125, Japan.

Naoki Okada (N)

Project for Vaccine and Immune Regulation, Laboratory of Vaccine and Immune Regulation (BIKEN), Graduate School of Pharmaceutical Sciences, Osaka University, 1-6 Yamadaoka, Suita, Osaka, 565-0871, Japan. okada@phs.osaka-u.ac.jp.
Laboratory of Vaccine and Immune Regulation (BIKEN), Graduate School of Pharmaceutical Sciences, Osaka University, 1-6 Yamadaoka, Suita, Osaka, 565-0871, Japan. okada@phs.osaka-u.ac.jp.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH